Skip to main content
. Author manuscript; available in PMC: 2019 Apr 9.
Published in final edited form as: Vaccine. 2017 Aug 1;35(37):4942–4951. doi: 10.1016/j.vaccine.2017.07.086

Table 1.

Passive transfer studies. A. Groups of 2 naïve rabbits were infused with the pooled immune serum (collected either 1, 3, 6 and 12 months post vaccination as described in Fig. 2) in volumes corresponding to a dilution of 20, 100, 500, 2500 or 12500 of the recipient’s blood volume for each vaccination cohort and compared to placebo. These animals were then challenged with HPV6, 16, 18, 31, 45 and 58 quazivirions (QV) and CRPV and papilloma size then scored 8 weeks later. The maximum dilution that shows complete protection is shown (EPPT). (nr) = not reliable.

Vaccine Month CRPV HPV6 HPV16 HPV18 HPV31 HPV45 HPV58
Placebo 1 <20 <20 <20 <20 <20 <20 <20
Placebo 3 <20 <20 <20 <20 <20 <20 <20
Placebo 6 <20 <20 <20 <20 <20 <20 <20
Placebo 12 <20 <20 <20 <20 <20 <20 <20
Fla69 1 <20 100 500 500 20 <20 20
Fla69 3 <20 <20 20 20 <20 <20 20
Fla69 6 <20 20 20 20 <20 <20 20
Fla69 12 <20 <20 <20 20 <20 <20 20
5XAL 1 <20 500 2500 500 20 20 100
5XAL 3 <20 100 20 100 <20 20 20
5XAL 6 <20 20 20 <20 <20 <20 20
5XAL 12 <20 20 <20 <20 <20 <20 <20
Fla32 6 <20 <20 <20 <20 <20 <20 <20
Fla32 12 <20 <20 <20 <20 <20 <20 <20
8XAL 6 <20 20 500 20 20 <20 20
8XAL 12 <20 20 <20 100 <20 <20 <20
Cervarix 6 <20 <20 2500 500 20 <20 20
Cervarix 12 <20 20 20 nr <20 <20 <20
Gardasil 6 <20 20 100 100 <20 <20 <20
Gardasil 12 <20 20 20 nr <20 <20 <20

suggests that the RG1 epitope-specific response may contribute to broad immunity.